Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Jared Gollob sold 5,613 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total transaction of $499,164.09. Following the completion of the sale, the insider owned 122,029 shares in the company, valued at $10,852,038.97. This represents a 4.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jared Gollob also recently made the following trade(s):

• On Wednesday, March 4th, Jared Gollob sold 4,895 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.30, for a total value of $417,543.50.
• On Monday, December 8th, Jared Gollob sold 49,307 shares of Kymera Therapeutics stock. The stock was sold at an average price of $88.67, for a total value of $4,372,051.69.

Kymera Therapeutics Stock Down 3.0%

Shares of Kymera Therapeutics stock opened at $83.52 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00. The business has a 50 day moving average price of $78.75 and a 200-day moving average price of $66.52. The company has a market cap of $6.82 billion, a PE ratio of -22.70 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.88) EPS. As a group, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the period. Smartleaf Asset Management LLC grew its holdings in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC increased its position in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period. Finally, Bessemer Group Inc. raised its stake in shares of Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Wall Street Analysts Forecast Growth

KYMR has been the topic of several analyst reports. Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Oppenheimer increased their price objective on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. BTIG Research cut their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Citigroup upped their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $123.00 price target on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.